In a big boost for Bharat BioTech, the Subject Expert Committee has approved the phase 3 trial data of Covaxin. The Covid-19 vaccine by Bharat BioTech shows 77.8% efficacy in the phase 3 trial. Bharat BioTech was only given emergency approval, and now it has got the approval of the phase III trial data. Their data shows that the phase III trials were conducted upon 25800 subjects.